Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
March 6, 2019

Data shows Novartis’ psoriasis drug is more effective than rival

Novartis has said that data from the Phase lllb CLARITY clinical trial shows that Cosentyx was more effective in treating patients with moderate-to-severe plaque psoriasis compared to Janssen’s Stelara (ustekinumab).

Novartis has said that data from the Phase IIIb CLARITY clinical trial shows that Cosentyx was more effective in treating patients with moderate-to-severe plaque psoriasis compared to Janssen’s Stelara (ustekinumab).

After 16 weeks of therapy, 68.4% of patients treated with Cosentyx did not experience the impact of skin disease on their quality of life (QoL), compared to 55.9% on Janssen’s Stelara, Novartis said.

A comparatively higher proportion of patients receiving Cosentyx achieved Dermatology Life Quality Index (DLQI) zero or one at week 12 and week 16.

Cosentyx is a fully-human biologic designed to specifically inhibit the interleukin-17A (IL-17A) cytokine known to be associated with the inflammation and development of psoriasis, psoriatic arthritis and ankylosing spondylitis.

The 52-week, multi-centre, randomised, double-blind CLARITY trial is being conducted to establish the superiority of 300mg Cosentyx compared to Stelara in patients suffering from moderate-to-severe plaque psoriasis.

“Our goal is to provide a treatment that targets all these manifestations and improves the quality of life of patients suffering from psoriatic diseases.”

Novartis initially announced data from the trial in January last year, reporting Cosentyx’s superiority in delivering clear and almost clear skin at 12 and 16 weeks. The skin clearance sustained until week 52.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

Nearly 66.5% and 72.3% of participants treated with Cosentyx met both co-primary endpoints of PASI 90 and Investigator’s Global Assessment (IGA) mod 2011 0/1, respectively.

The figures were 47.9% and 55.4%, respectively, in the case of patients treated with Stelara.

Novartis Immunology, Hepatology and Dermatology medical affairs worldwide head Sam Khalil said: “Over two-thirds of psoriasis patients experience persistent manifestations beyond skin plaques including nail, scalp, palmoplantar psoriasis as well as joints involvement.

“Our goal is to provide a treatment that targets all these manifestations and improves the quality of life of patients suffering from psoriatic diseases, with a proven long-term safety and efficacy.”

The company also reported new findings from 441 Chinese patients participating in a Phase III trial being performed to evaluate the safety and efficacy of Cosentyx in moderate to severe plaque psoriasis.

Data revealed 97.7% of patients treated with 300mg Cosentyx experienced PASI 75 and 80.9% achieved PASI 90 by week 12, while 87% of patients reached PASI 90 by week 16.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU